Alectinib has shown promising antitumour activity in patients with ALK-rearranged non-small-cell lung cancer (NSCLC) that is resistant to crizotinib, researchers report.
“[A]lmost all patients with ALK-rearranged NSCLC invariably progress, with the CNS [central nervous system] being a common site of relapse”, note researcher Sai-Hong Ou (University of California Irvine School of Medicine, Orange, USA) and team. Progression in the CNS and resistance to crizotinib mean that “we urgently need novel ALK inhibitors that can overcome acquired ALK resistance, can cross the blood–brain barrier, and are well tolerated”, the researchers add.
In the current dose-finding part of the AF-002JG study, 47 patients with ALK-rearranged NSCLC began oral alectinib twice a day a median of 18 days after discontinuing crizotinib. The dose varied from 300 to 900 mg.
READ FULL ARTICLE From News Medical